Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16529577 | 0.87 | DDR1 (0.51) | DDR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL16529560 | 0.86 | DDR1 (0.39) | DDR1KMT2A | |
| SCHEMBL16676511 | 0.85 | DDR1 (0.39) | DDR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL16676298 | 0.80 | KMT2A (0.37) | DDR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL16676499 | 0.79 | GAA (0.38) | DDR1KMT2A | |
| SCHEMBL16676433 | 0.78 | DDR1 (0.40) | DDR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL16676176 | 0.76 | DDR1 (0.44) | DDR1KMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL16676266 | 0.75 | GAA (0.43) | KMT2AMEN1 | |
| SCHEMBL16676174 | 0.74 | DDR1 (0.42) | DDR1MAP2K1 | |
| SCHEMBL16676536 | 0.73 | DDR1 (0.38) | DDR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015060373-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | 中外製薬株式会社 | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | DDR1 4404/4885KMT2A 2733/4885MEN1 2307/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | DDR1 4404/4885KMT2A 2733/4885MEN1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.